Clinical Trial Update: Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating SyB L-0501 in combination with Rituximab for relapsed/refractory diffuse large B-cell lymphoma has completed, with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• SyB L-0501

Snippet

Sponsor: SymBio Pharmaceuticals | Conditions: Non-Hodgkin's Lymphoma, Lymphoma, Large Cell | Phase 2 | Status: COMPLETED | Results posted: 2013-07-04